Author Interviews, Breast Cancer, Scripps / 25.01.2015
Novel Compound May Shut Down Pancreatic and Triple Negative Breast Cancer Cells
MedicalResearch.com Interview with:
Dr. Patrick Griffin PhD
Professor and Chairman Department of Molecular Therapeutics
Director of the Translational Research Institute
Scripps Research Institute, Jupiter, Florida
MedicalResearch.com: What is the background for this study? What are the main findings?
Dr. Griffin: We identified a novel synthetic compound known as SR1848 that sharply inhibits the activity and expression of “liver receptor homolog-1” or LRH-1, a protein that plays an important role in the progression of breast and pancreatic cancers.
Our new study shows that SR1848 removes LRH1 from DNA, shutting down expression of LRH-1 target genes, and halts cell proliferation. It’s a novel compound that appears to be a promising chemical scaffold for fighting tumors that are non-responsive to standard therapies. (more…)